Akif Turna
Bayram Kıran
Engin Ozar
Hande Turna
Cem Ahmet Mercan
Nur Büyükpınarbaşılı
Ayhan Bilir
Günnur Deniz

Abstract

Objectives:

This study aims to investigate the anti-tumoral, anti-angiogenic and immunologic effects of interleukin-12 (IL-12) in combination with protamine in intracranially inoculated rat C6 glioma model.

Material and methods:

A 12-week-old 60 female Sprague-Dawley rats with a mean weight of 208±19 g were divided into six groups: C6 glioma cells were inoculated in group A; tumor in combination with recombinant IL-12 (rIL-12) 10 ng were inoculated intracranially in group B; rIL-12 10 ng intracranially with protamine 60 mg/kg subcutaneously were given to group C; protamine subcutaneously was given to group D; vehicle was given subcutaneously to group E; rIL-12 10 ng was subcutaneously given with protamine and tumor was inoculated in group F.

Results:

Intracranial rIL-12 and protamine exerted both anti-tumoral and anti-angiogenic effects (p=0.001). Intracranial rIL-12 administration significantly diminished peripheral blood Th2 cell ratio (p=0.03) and improved survival of the rats (p=0.001). Protamine monotherapy or in combination with IL-12 showed no immunologic alteration in T helper cell population.

Conclusion:

Recombinant IL-12 and protamine are effective against intracranially inoculated glioma, improve survival significantly as monotherapy or combination therapy and alter T helper cell cytokine secretion profile in favor of Th2 in rats.

Keywords:

Angiogenesis, C6, glioma, interleukin-12, lymphocyte, protamine, Th1 cell, Th2 cell

VOLUME

1

,

ISSUE

3
December 2013

Correspondence

Akif Turna

Email

Received

Accepted

Published

Suggested Citation

DOI

License

This work is licensed under the Creative Commons Attribution-NonCommercial-Non-Derivatives 4.0 International License (CC BY-NC-ND 4.0). License